Navigation Links
Ninety Percent of Polled Pain Care Professionals Express Fear of Regulation
Date:9/7/2007

Delegates to PAINWeek 2007 Provide Sampling of Healthcare Professionals in

Context of Pain Management

LAS VEGAS, Sept. 7 /PRNewswire/ -- When asked to assess their level of fear of government regulation of their pain management practices, nearly half of 200 health care professionals surveyed during PAINWeek 2007 said the threat of regulation had "significant" or "high" impact on their practice. Approximately 90 percent reported at least "low" impact.

The survey results come amid growing controversy surrounding use of opioids - the strongest class of painkillers - and physicians' willingness to prescribe them.

In March, the state of Washington became the first state in the nation to adopt a suggested daily limit on opioid doses.

"What is at stake here is the well-being of tens of millions of Americans who suffer with pain," explained American Society of Pain Educators Executive Director B. Eliot Cole, MD, MPA. "Clearly, increased regulation would have a disastrous, chilling effect on care givers' ability to manage patients' bona fide, diagnosed pain."

Additionally, when asked about the importance of putting oversight of medical decisions in the hands of medical professionals as opposed to law enforcement regulators, 69 percent of those surveyed called that "most important" to their ability to manage their patients' pain.

According to 43 percent of PAINWeek delegates, lack of adequate pain management education during their professional training has a high-impact on their ability to provide appropriate pain management to their patients.

Nearly a dozen national medical associations and 700 delegates devoted to the practice of pain management are gathered at PAINWeek 2007, the first conference of its kind, in Las Vegas. The four-day conference provides a unique environment for the participating organizations to share their expertise with frontline healthcare practitioners.

Participating organ
'/>"/>

SOURCE PAINWeek 2007
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Vaccine Ninety Percent Effective Against Cervical Cancer
2. Pharmacia may take 51.5 percent Abbott stake
3. 45 Percent Of Errors In Cancer Diagnosis Harm The Patient
4. Zyflamend inhibits 78 percent of prostate cancer cells
5. Births Out Of Wedlock Increased To 42 Percent in 2004 in the UK
6. Community Dentists To Receive 10 Percent Salary Boost
7. NHS Forced to Borrow Money at Rates of 10 percent
8. Almost 30 Percent Dentists Refuse To Sign NHS Contracts
9. Polyunsaturated Fats And Vitamin E Cut MND Risk By 60 Percent
10. More Than 50 Percent Indians Aged Over 40 Have Diabetes, High Blood Pressure
11. Around 20 Percent Take-Out Foods Are Unhygienic
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/8/2009)...n. 8 New York City Mayor Michael R...Education Day" and presented a proclamation to Ilc...ucation Association) and developer of Brain Educat...to enhance health, well-being, and mental ability ... leader regarding the power of individuals to chan...
(Date:1/8/2009)...Va., Jan. 8 Today, the ...along with several national leadership organizatio...ciples of hospice care and protection of the Medic...gether in sharing this unified message about end-o...e and Palliative Medicine, Hospice and Palliative ...
(Date:1/8/2009)...ugar sitting on the surface of cancer cells are ke...th treating and stopping the spread of certain typ...state, breast, ovarian and lung, among others. Ar...e Gateway for Cancer Research, an Illinois-based p...ranco, M.D., Ph.D., and her co-workers at the Moor...
(Date:1/8/2009)...ts Prenatal Solution Key Factor in Decision for Fl...LANDO, Fla., Jan. 8 Alls...LC, one of the largest multi-specialty group pract...the Allscripts Enterprise(TM) Electronic Health Re...ians in 18 offices across Central Florida. , ,...
Breaking Medicine News(10 mins):Health News:NYC Mayor Michael R. Bloomberg Declares January 8th 'IBREA Brain Education Day' 2Health News:National End-of-Life Organizations Release Consensus Statement on Hospice, the Medicare Hospice Benefit, and Key Issues for the Future 2Health News:National End-of-Life Organizations Release Consensus Statement on Hospice, the Medicare Hospice Benefit, and Key Issues for the Future 3Health News:National End-of-Life Organizations Release Consensus Statement on Hospice, the Medicare Hospice Benefit, and Key Issues for the Future 4Health News:National End-of-Life Organizations Release Consensus Statement on Hospice, the Medicare Hospice Benefit, and Key Issues for the Future 5Health News:National End-of-Life Organizations Release Consensus Statement on Hospice, the Medicare Hospice Benefit, and Key Issues for the Future 6Health News:National End-of-Life Organizations Release Consensus Statement on Hospice, the Medicare Hospice Benefit, and Key Issues for the Future 7Health News:Novel prostate cancer vaccine taking aim at cancer cell 'sweet spot' 2Health News:Physician Associates, LLC Selects Allscripts Electronic Health Record to Connect and Automate 80 Physicians 2Health News:Physician Associates, LLC Selects Allscripts Electronic Health Record to Connect and Automate 80 Physicians 3Health News:Physician Associates, LLC Selects Allscripts Electronic Health Record to Connect and Automate 80 Physicians 4
...d test called Cystatin-C for predicting cardiovasc...malfunction. Earlier test that was used was creati...e more effective and better predictor than the ear...hree types of cardiovascular risks: low, medium an...
...erial infection of the lungs, says a study publish...rchers had studied persons of age between 2 to 49 ...rsons with invasive pneumococcal disease, 10 perso...as controls. Asthma was defined by the study as pr...
...ity Baptist Medical Center, US, have found that lo...hildren with cancer, and thus limits the side effe...oked into the chemotherapy given to children suffe...(ALL). Patients suffering from for this type of ch...
...accine for treating Alzheimer’s disease may be abl... use the bodies own immunity to resist the onset a...t affect people above the age of 40 years. The fi...ls which began some time back, was when scientists...
Other Medicine News:
(Date:1/7/2009)... , FREDERICK, Md., Jan. 7 ImQue...bmission of an IND application to the Food and Dru... for their lead pyrimidinedione HIV inhibitor IQP-... studies in the first quarter of 2009. IQP-0410 is...marily acts as a nonnucleoside reverse transcripta...
(Date:1/6/2009)... , Program Expands on Successful Results from p... Jan. 7 Vital Therapies, Inc. (VTI...ease, today announced patient enrollment has begun... 2 clinical trial that will study the Extracorpore...atients with Acute Liver Failure (ALF) under three...
(Date:1/6/2009)... , ROCKVILLE, Md., Jan. 6 /PRNewswire-USNewswir...utical company focused on diseases of epidemic pot...candidate for the treatment of tuberculosis (TB), ...wly awarded clinical program contract to Dynport V...e contract, awarded by the National Institute of A...
(Date:1/5/2009)... , SAN DIEGO, Jan. 5 Cylene Pha... a Phase I clinical trial of its oral CK2 protein ...ed solid tumors, Castleman,s disease, or multiple ...calating trial are determination of safety, tolera... appropriate dose for Phase II trials. In addition...
Breaking Medicine Technology:ImQuest Submits Investigational New Product Application to the Food and Drug Administration to Initiate HIV Therapeutic Clinical Trials with IQP-0410 2ELAD(R) Liver Support System Study Initiated at Multiple U.S. Centers 2ELAD(R) Liver Support System Study Initiated at Multiple U.S. Centers 3Sequella Lead Drug Compound SQ109 Selected for Phase 1B Clinical Trial Program 2Sequella Lead Drug Compound SQ109 Selected for Phase 1B Clinical Trial Program 3Cylene Pharmaceuticals Initiates Phase I Trial With CX-4945 -Breakthrough First-in Class Inhibitor of CK2 2Cylene Pharmaceuticals Initiates Phase I Trial With CX-4945 -Breakthrough First-in Class Inhibitor of CK2 3Greenway Medical Technologies EHR Solution PrimeSuite Wins Three Best in KLAS Awards 32167 1Greenway Medical Technologies EHR Solution PrimeSuite Wins Three Best in KLAS Awards 32167 2Greenway Medical Technologies EHR Solution PrimeSuite Wins Three Best in KLAS Awards 32167 3Greenway Medical Technologies EHR Solution PrimeSuite Wins Three Best in KLAS Awards 32167 4Sage Software Healthcare Appoints Kathleen Henry Senior Vice President Customer Service 32165 1Sage Software Healthcare Appoints Kathleen Henry Senior Vice President Customer Service 32165 2Immune System Works Better at Night 32164 1Immune System Works Better at Night 32164 2Later School Start Time Cuts Teens Car Crash Risk 32162 1Later School Start Time Cuts Teens Car Crash Risk 32162 2Later School Start Time Cuts Teens Car Crash Risk 32162 3
...)--Jun 4, 2007 - Introgen Therapeutics, Inc.,(NASD... today,reported updated Phase 2 data demonstrating...umor responses and increased,survival following AD...us cell carcinoma of the head and neck. The data (... meeting of the American,Society of Clinical Oncol...
...se 2 Clinical Data Published at the American,Socie...GO, June 04, 2007 /PRNewswire-FirstCall/ -- Pharmi...m its Phase II,multi-center clinical study of Amr...nthracycline currently in development,for the trea...dicate favorable interim results in terms of respo...
Other Medicine Technology:Introgen Reports Updated Phase 2 Advexin Data Correlating Improved,Survival, Tumor Responses and Predictive p53 Biomarker 2Introgen Reports Updated Phase 2 Advexin Data Correlating Improved,Survival, Tumor Responses and Predictive p53 Biomarker 3Introgen Reports Updated Phase 2 Advexin Data Correlating Improved,Survival, Tumor Responses and Predictive p53 Biomarker 4Pharmion's Amrubicin Shows Encouraging Results Compared to Standard,of Care in Second Line Treatment of Small Cell Lung Cancer 2Pharmion's Amrubicin Shows Encouraging Results Compared to Standard,of Care in Second Line Treatment of Small Cell Lung Cancer 3Pharmion's Amrubicin Shows Encouraging Results Compared to Standard,of Care in Second Line Treatment of Small Cell Lung Cancer 4
The 15 and 18 Sony Flat Screen Monitors with articulating arm can be used in conjunction with existing surgical monitors or as replacements.
Colour video monitors.
The A3 3-Chip Camera includes digital processing, seamless autoshutter, industry-leading reliability, white balance with memory function, ease of operation, and a 2 year warranty.
Camera and light source in one compact "Plug-and-Play" device.
Medicine Products: